
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Ellie Chabi, MD, therapeutic area head for Glaucoma & Neuroprotection, lead for Artificial Intelligence Programs within Global Biomedical Science for Santen, shares insight on the company's role in the panel discussion focusing on new developments and discoveries in the glaucoma space during the 2020 Glaucoma 360 annual meeting in San Francisco, California.






